Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Kaufman

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
FEBS Letters|February 25, 2014
p53: the barrier to cancer stem cell formationRonit Aloni-Grinstein, Yoav Shetzer, Tom Kaufman, et al.
International Journal of Cancer|December 24, 2016
Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitorsYoav Shetzer, Yael Napchan, Tom Kaufman, et al.
Nature Communications|May 18, 2022
Visual barcodes for clonal-multiplexing of live microscopy-based assaysTom Kaufman, Erez Nitzan, Nir Firestein, et al.
Antibodies (Basel, Switzerland)|January 23, 2025
A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART<sup>®</sup> Molecule for Treatment of Solid TumorsRenhua R Huang, Michael Spliedt, Tom Kaufman, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
FEBS Letters|February 25, 2014
p53: the barrier to cancer stem cell formationRonit Aloni-Grinstein, Yoav Shetzer, Tom Kaufman, et al.
International Journal of Cancer|December 24, 2016
Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitorsYoav Shetzer, Yael Napchan, Tom Kaufman, et al.
Nature Communications|May 18, 2022
Visual barcodes for clonal-multiplexing of live microscopy-based assaysTom Kaufman, Erez Nitzan, Nir Firestein, et al.
Antibodies (Basel, Switzerland)|January 23, 2025
A Strategy for Simultaneous Engineering of Interspecies Cross-Reactivity, Thermostability, and Expression of a Bispecific 5T4 x CD3 DART<sup>®</sup> Molecule for Treatment of Solid TumorsRenhua R Huang, Michael Spliedt, Tom Kaufman, et al.
Pageof 1